Balsalazide

Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].

Product Specifications

CAS Number

[80573-04-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related; STAT

Type

Reference compound

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Balsalazide.html

Concentration

10mM

Purity

99.20

Solubility

1M NaOH : 50 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O

Molecular Formula

C17H15N3O6

Molecular Weight

357.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31 (8) :1453-61.|[2]Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49 (6) : p. 783-789.|[3]Seema A Patil, et al. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2 (2) :177-84.